Clinical Trial

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Name: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma — clinical trial record (NCT05650749)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GPC2

Enrolling by Invitation Phase 1

View on ClinicalTrials.gov →

Summary

This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Enrolling by Invitation 2026-08-15

Trial Details

NCT Number	NCT05650749
Lead Sponsor	Stephan Grupp MD PhD Collaborators: Children's Hospital of Philadelphia, Gilead Sciences, University of Pennsylvania, National Cancer Institute (NCI), Kite, A Gilead Company
Conditions	Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
Enrollment	45 participants
Start Date	2023-05-23
Primary Completion	2028-01-30 (estimated)
Study Completion	2030-01-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-14